These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32740556)

  • 1. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 3. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.
    Katz RB; Toprak M; Wilkinson ST; Sanacora G; Ostroff R
    Gen Hosp Psychiatry; 2018; 54():62-64. PubMed ID: 30100209
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
    Ludwig VM; Sauer C; Young AH; Rucker J; Bauer M; Findeis H; Ritter P
    CNS Drugs; 2021 Aug; 35(8):881-892. PubMed ID: 34283390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases.
    Schmidt FM; Kirkby KC; Himmerich H
    Psychiatr Danub; 2014 Sep; 26(3):288-90. PubMed ID: 25191779
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
    Bartova L; Vogl SE; Stamenkovic M; Praschak-Rieder N; Naderi-Heiden A; Kasper S; Willeit M
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2183-4. PubMed ID: 26302763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
    Singh B; Bobo WV; Rasmussen KG; Stoppel CJ; Rico JA; Schak KM; Biernacka JM; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31721482
    [No Abstract]   [Full Text] [Related]  

  • 8. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of monoamine oxidase inhibitors in primary care.
    Culpepper L
    J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 12. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
    Rihmer Z; Dome P; Gonda X
    J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
    Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
    J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for depression.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
    [No Abstract]   [Full Text] [Related]  

  • 16. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
    J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
    [No Abstract]   [Full Text] [Related]  

  • 17. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
    J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].
    Köhler S; Stöver LA; Bschor T
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):228-36; quiz 237-8. PubMed ID: 24710679
    [No Abstract]   [Full Text] [Related]  

  • 20. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
    Flockhart DA
    J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.